References:
1. Klein A, Landthaler M, Karrer S. Pityriasis Rubra Pilaris. American Journal of Clinical Dermatology. 2010;11(3):157-70.
2. Wang D, Chong VC, Chong WS, Oon HH. A Review on Pityriasis Rubra Pilaris. American journal of clinical dermatology. 2018;19(3):377-90.
3. Brown F, Badri T. Pityriasis Rubra Pilaris. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Talel Badri declares no relevant financial relationships with ineligible companies.: StatPearls Publishing
Copyright © 2023, StatPearls Publishing LLC.; 2023.
4. Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. American journal of clinical dermatology. 2010;11(3):157-70.
5. Cohen PR, Prystowsky JH. Pityriasis rubra pilaris: A review of diagnosis and treatment. Journal of the American Academy of Dermatology. 1989;20(5, Part 1):801-7.
6. GRIFFITHS WAD. Pityriasis rubra pilaris*. Clinical and Experimental Dermatology. 1980;5(1):105-12.
7. Cohen PR, Prystowsky JHJJotAAod. Pityriasis rubra pilaris: a review of diagnosis and treatment. 1989;20(5):801-7.
8. Roenneberg S, Biedermann T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. Journal of the European Academy of Dermatology and Venereology: JEADV. 2018;32(6):889-98.
9. Guenther J, Novack D, Kamath S, Worswick S. Treatment Options for Juvenile Pityriasis Rubra Pilaris. Paediatric drugs. 2023;25(2):151-64.
10. Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents: A Retrospective Analysis From an Academic Medical Center. JAMA Dermatology. 2014;150(1):92-4.
11. Sadowska M, Narbutt J, Skibińska M, Lesiak A. Pros and cons of using systemic acitretin in the pediatric population. Postepy dermatologii i alergologii. 2022;39(1):34-8.
12. Rosenbach A, Lowe NJ. Pityriasis rubra pilaris and cyclosporine. Archives of dermatology. 1993;129(10):1346-8.
13. Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology (Basel, Switzerland). 2000;200(4):324-7.
14. Amber T, Tabassum S. Cyclosporin in dermatology: A practical compendium. 2020;33(6):e13934.
15. Marsili F, Travaglini M, Stinco G, Manzoni R, Tiberio R, Prignano F, et al. Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. The Journal of dermatological treatment. 2022;33(1):401-7.
16. Frantz T, Wright EG, Balogh EA, Cline A, Adler-Neal AL, Feldman SR. Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis. Children (Basel, Switzerland). 2019;6(11).
17. Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. British Journal of Dermatology. 2003;149(1):202-3.
18. Chen P-J, Liang J-Y, Li C-X, Zhang X-B. Successful Treatment of Severe Pityriasis Rubra Pilaris with Cyclosporine A in An Infant. 2022;05(02):110-2.
19. Craiglow BG, Boyden LM, Hu R, Virtanen M, Su J, Rodriguez G, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. Journal of the American Academy of Dermatology. 2018;79(3):487-94.
20. Signa S, Campione E, Rusmini M, Chiesa S, Grossi A, Omenetti A, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatric rheumatology online journal. 2019;17(1):38.
21. Chiramel MJ, Sathishkumar D, Edison ES, George R. Two cases of CARD14-associated papulosquamous eruption from India. Pediatric dermatology. 2020;37(4):692-4.
22. Liang JY, Ye RX, Tian X, Zhang SQ, Zhang XB. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review. Dermatologic therapy. 2020;33(6):e14097.
23. Lora V, De Felice C, Cota C, Graceffa D, Morrone A, Bonifati C. A case of juvenile pityriasis rubra pilaris type III successfully treated with etanercept. Dermatologic therapy. 2018;31(1).
24. Bonomo L, Raja A, Tan K, Guttman-Yassky E. Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl. JAAD case reports. 2018;4(2):206-10.
25. Kromer C, Lippert U, Schön MP, Mössner R. Treatment of pityriasis rubra pilaris: a case series of 28 patients. European journal of dermatology : EJD. 2020;30(5):569-79.
26. Maloney NJ, Hisaw LD, Worswick S. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation. Dermatologic therapy. 2017;30(6).
27. Kim BR, Chae JB, Park JT, Byun SY, Youn SW. Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient. The Journal of dermatology. 2015;42(11):1122-3.